DL‐PDT for AK: multicentre trial comparing BF‐200 ALA with MAL

Räsänen, Janne; Neittaanmäki, Noora; Ylitalo, Leea; Hagman, J.; Rissanen, Pekka; Ylianttila, Lasse; Salmivuori, Mari; Snellman, Erna; Grönroos, Mari

doi:10.1111/bjd.18181

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The excellent result was still observed 12 months after the completion of treatment [23]. Räsänen et al [24] compared the cosmetic outcome of PDT with the use of either BF-200 ALA or MAL in 69 patients with numerous AK lesions. In their study, 12 months after treatment completion, the cosmetic outcome was excellent or good in >90% of the studied patients, regardless of the used PS.…”

Section: Discussionmentioning

confidence: 99%

Topical Photodynamic Therapy with Different Forms of 5-Aminolevulinic Acid in the Treatment of Actinic Keratosis

et al. 2022

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is safe and effective in the treatment of patients with actinic keratosis (AK). The aim of the study was to assess the efficacy, tolerability and cosmetic outcome of topical PDT in the treatment of AKs with three forms of photosensitizers: 5-Aminolevulinic acid hydrochloride (ALA-HCl), 5-Aminolevulinate methyl ester hydrochloride (MAL-HCl) and 5-Aminolevulinate phosphate (ALA-P). The formulations were applied onto selected scalp/face areas. Fluorescence was assessed with a FotoFinder Dermoscope 800 attachment. Skin areas were irradiated with Red Beam Pro+, Model APRO (MedLight GmbH, Herford, Germany). Applied treatments were assessed during the PDT as well as 7 days and 12 weeks after its completion. Ninety-four percent of patients rated obtained cosmetic effect excellent. The efficacy of applied PSs did not differ significantly. However, pain intensity during the PDT procedure was significantly lower in the area treated with ALA-P (5.8 on average) in comparison to the areas treated with ALA-HCl or MAL-HCl (7.0 on average on 0–10 scale). Obtained results show that ALA-P may undergo more selective accumulation than ALA-HCl and MAL-HCl. Our promising results suggest that PDT with the use of ALA-P in AK treatment may be an advantageous alternative to the already used ALA-HCl and MAL-HCl.

show abstract

Section: Discussionmentioning

confidence: 99%

Topical Photodynamic Therapy with Different Forms of 5-Aminolevulinic Acid in the Treatment of Actinic Keratosis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…ALA hydrochloride (ALA HCl, Gleolan) was recently approved by the U.S. Metvix application under daylight has the same effect as in the combination with blue light PDT and that ALA is more effective than MALA in DL-PDT 157,158 .In the case of DL-PDT, the quantification of light dose, which is directly dependent on the environmental conditions, is of great importance 159 .…”

Section: X41 Clinically Approved Photosensitizersmentioning

confidence: 99%

Porphyrinoids for Photodynamic Therapy

Melissari

Williams

Senge

2021

Applications of Porphyrinoids as Functional Materials

View full text Add to dashboard Cite

This chapter gives an overview of porphyrinoids for use in photodynamic therapy. It covers the characteristics, properties and current treatments or porphyrin-based photosensitizers. The first section introduces the phototherapy and photodynamic therapy concepts and gives an overview of the principles of photophysical and photopharmacological aspects of potential photosensitizers. The subsequent section summarizes current treatments of clinically approved photosensitizers and those under development. A brief survey of the strategies for singlet oxygen generation enhancement and drug-delivery improvements is described in the last Section.

show abstract

“…These advantages have led to the development and approval of ALA-PDT as a first line clinical approach for the treatment of cancerous and precancerous skin lesions e.g Bowen's disease, basal skin carcinomas, and actinic keratosis that would otherwise require significant conventional surgery [9], most recently with the application of the UVA component of sunlight for activation of PpIX (daylight PDT) [10][11][12]. ALA-induced PpIX production is now an established tool in PDD and has also recently been approved by the FDA and EMA for fluorescence-guided resection of malignant tumours in the brain [13,14].…”

Section: Introductionmentioning

confidence: 99%